Regent Pacific (HKG:0575) received a milestone payment of $4.5 million from Fosun Wanbang (Jiangsu) Pharmaceutical Group on Monday.
The payment was received under a licence and collaboration arrangement related to Senstend between the parties, according to a Tuesday bourse filing.
Fosun Wanbang (Jiangsu) Pharmaceutical Group is expected to begin the commercialization of Senstend in China, leading to further milestone and royalty payments to the company.
Fosun Wanbang (Jiangsu) Pharmaceutical Group is a unit of Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196).